Pharsight

Xtandi is owned by Astellas.

Xtandi contains Enzalutamide.

Xtandi has a total of 3 drug patents out of which 0 drug patents have expired.

Xtandi was authorised for market use on 31 August, 2012.

Xtandi is available in capsule;oral dosage forms.

Xtandi can be used as the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc), treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-sensitive prostate cancer.

The generics of Xtandi are possible to be released after 13 August, 2027.

Application	Filing Date	Opposition Party	Legal Status
EP11184401A	2015-12-18	Generics (U.K.) Limited	Revoked
EP06748863A	2012-10-18	Fickert, Stefan	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709517	ASTELLAS	Diarylhydantoin compounds	Aug, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941	ASTELLAS	Treatment of hyperproliferative disorders with diarylhydantoin compounds	May, 2026 (2 years from now)
US8183274	ASTELLAS	Treatment of hyperproliferative disorders with diarylhydantoin compounds	Aug, 2026 (3 years from now)

Do you want to check out XTANDI patents from before 2022?

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 16, 2022

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 31 August, 2012

Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: CAPSULE;ORAL